Zaynich Approval: How Big Is It For Wockhardt?

What Drove This Radical Antibiotic Research?

Scientific Bet, Business Bet, Or Innovation?

How Did You Stay The Course Through Crisis

Can This Innovation Stay Ahead Of Rivals?

Will Zaynich Lead To Higher R&D Investments?

Is Wockhardt Entering Its Biggest Growth Phase

Can Zaynich Thrive Despite A Smaller Market?

Message To India's Pharma Innovators?

What Can Entrepreneurs Learn From Persistence?

Wockhardt's FDA approval of Zaynich marks a historic first, the only drug entirely discovered and developed by an Indian company to clear US-FDA scrutiny. ET’s pharma editor Vikas Dandekar and Rica Bhattacharyya talk to Habil Khorakiwala, Chairperson of Wockhardt who unpacks the 25-year innovation journey behind this milestone. From a deliberate pivot to antibiotics when big pharma was exiting the space, to navigating financial turbulence, asset sales, and regulatory hurdles, Khorakiwala reflects on strategic patience and scientific conviction. He also outlines peak sales projections of $1.5–2 billion, the US commercial roadmap led by daughter Zahabiya, and a robust pipeline of blockbusters ahead.

You can follow Vikas Dandekar on his social media: X or Linkedin and Rica Bhattacharyya on her X and Linkedin

Listen in to the episode of Corner Office Conversation with Sridhar Vembu, CEO, of Zoho Corporation, Corner Office Conversation with Gunjan Soni, Country Managing Director, Youtube India, Corner Office Conversation with  G.V. Prasad, Co-Chairman and Managing Director Dr Reddy’s Laboratories Ltd, Corner Office Conversation with Rajan Anandan, Managing Director, Peak XV & Surge and much more.


Catch the latest episode of “Corner Office Conversation” on: Spotify, Amazon Music, Apple Podcasts,and wherever you get your podcasts from.

Wockhardt's FDA approval of Zaynich marks a historic first, the only drug entirely discovered and developed by an Indian company to clear US-FDA scrutiny. ET&rsquo;s pharma editor Vikas Dandekar and Rica Bhattacharyya talk to Habil Khorakiwala, Chairperson of Wockhardt who unpacks the 25-year innovation journey behind this milestone. From a deliberate pivot to antibiotics when big pharma was exiting the space, to navigating financial turbulence, asset sales, and regulatory hurdles, Khorakiwala reflects on strategic patience and scientific conviction. He also outlines peak sales projections of $1.5&ndash;2 billion, the US commercial roadmap led by daughter Zahabiya, and a robust pipeline of blockbusters ahead. You can follow Vikas Dandekar on his social media: <a href="https://twitter.com/VikasReports">X</a> or <a href="https://www.linkedin.com/in/vikas-dandekar-2a0a619">Linkedin</a> and Rica Bhattacharyya on her <a href="https://x.com/RicaB_ET">X</a> and <a href="https://www.linkedin.com/in/rica-bhattacharyya-72b24a11/">Linkedin </a>Listen in to the episode of<a href="https://podcasts.apple.com/in/podcast/corner-office-conversation-with-sridhar-vembu-ceo-of/id1827451035?i=1000731722117"> Corner Office Conversation with Sridhar Vembu, CEO, of Zoho Corporation</a>,<a href="https://podcasts.apple.com/in/podcast/corner-office-conversation/id1827451035?i=1000731513423"> Corner Office Conversation with Gunjan Soni, Country Managing Director, Youtube India</a>,<a href="https://podcasts.apple.com/in/podcast/corner-office-conversation/id1827451035?i=1000756655695"> Corner Office Conversation with&nbsp; G.V. Prasad, Co-Chairman and Managing Director Dr Reddy&rsquo;s Laboratories Ltd</a>,<a href="https://podcasts.apple.com/in/podcast/corner-office-conversation/id1827451035?i=1000748828081"> Corner Office Conversation with Rajan Anandan, Managing Director, Peak XV &amp; Surge</a> and<a href="https://podcasts.apple.com/in/podcast/corner-office-conversation/id1827451035"> much more</a>.
 Catch the latest episode of &ldquo;Corner Office Conversation&rdquo; on:<a href="https://open.spotify.com/show/4fq4hKHPZO3MVDNhtOQ5OU?si=99e033dfb01a44c7"> Spotify</a>,<a href="https://music.amazon.com/podcasts/1f0c9fc5-f702-4a84-bd7d-4f010bea72a5/corner-office-conversation"> Amazon Music</a>,<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777"> Apple Podcasts</a>,and wherever you get your podcasts from.

Corner Office Conversation is The Economic Times’ flagship interview podcast featuring unfiltered, one-on-one conversations with some of India and the world’s most powerful business leaders.

Hosted by ET’s top journalists and editors, this fortnightly show goes beyond headlines and press releases to explore how CEOs and founders think, decide, and lead in an era of disruption.

From Marc Benioff (Salesforce), Dara Khosrowshahi (Uber), and Roland Busch (Siemens) to Adar Poonawalla (Serum Institute), Suresh Narayanan (Nestlé India), and Ravi Kumar S (Cognizant), these conversations uncover personal leadership playbooks, global strategy pivots, lessons from failures, and bold visions for the future — across industries like tech, healthcare, manufacturing, finance, and consumer goods.

New episodes drop every alternate Monday.

Corner Office Conversation is The Economic Times&rsquo; flagship interview podcast featuring unfiltered, one-on-one conversations with some of India and the world&rsquo;s most powerful business leaders.
Hosted by ET&rsquo;s top journalists and editors, this fortnightly show goes beyond headlines and press releases to explore how CEOs and founders think, decide, and lead in an era of disruption.
From Marc Benioff (Salesforce), Dara Khosrowshahi (Uber), and Roland Busch (Siemens) to Adar Poonawalla (Serum Institute), Suresh Narayanan (Nestl&eacute; India), and Ravi Kumar S (Cognizant), these conversations uncover personal leadership playbooks, global strategy pivots, lessons from failures, and bold visions for the future &mdash; across industries like tech, healthcare, manufacturing, finance, and consumer goods.
New episodes drop every alternate Monday.